Biopharma’s 20 highest-paid CEOs of 2023, earning $20M+ pay packages

The best-paid CEOs of 2023 fall largely into two groups: They’re either running some of the world’s biggest drugmakers, or they were given huge incentive packages in their first year on the job or as head of a newly-public company.

Endpoints News reviewed hundreds of annual proxy filings across biopharma. This is the first article in a series examining CEO and employee pay trends, after analyzing over 500 CEO pay packages last year. Like our analysis of 2022 pay packages, the top 20 CEOs brought in paydays valued at over $20 million.

The top-paid list has its staples in pharma giant CEOs like Amgen’s Bob Bradway, Pfizer’s Albert Bourla, and Eli Lilly’s David Ricks. But it also has some smaller biotechs dishing out equally hefty awards at startups like Neumora Therapeutics, Arcellx, and Vir Biotechnology.

As in years past, Endpoints used the estimated fair value of newly-issued…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks